Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Non-Hodgkin Lymphomas

• ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma
• Four-Year Follow-up from ZUMA-5 Demonstrates Continued Durable Response and Long-Term Survival in Patients with Relapsed/Refractory Follicular Lymphoma
• ZUMA-7 Overall Survival Subgroup Analysis in Patients Aged 65+ Shows that Age Alone is not a Barrier to Receiving CAR T

https://www.biospace.com/article/releases/analyses-of-kite-s-yescarta-car-t-cell-therapy-support-curative-potential-in-patients-with-non-hodgkin-lymphomas/